title: Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist.
abstract: Treating patients with cancer with infused or injected oncolytics is a core component of outpatient oncology practice. Currently, practices purchase drugs and then bill insurers, colloquially called "buy and bill." Reimbursement for these drugs is the largest source of gross revenue for oncology practices, and as the prices of cancer drugs have grown over time, these purchases have had significant impact on the financial health of practices and pose a risk that jeopardizes the ability of many practices to operate and provide patient care. Medicare Part B spending on drugs is under political scrutiny because of federal spending pressures, and the margin between buy and bill, lowered to 6% by the Medicare Modernization Act and further decreased to 4.3% by sequestration, is a convenient and popular target of budgetary discussions and proposals, scored to save billions of dollars over 10-year budget windows for each percentage-point reduction. Alternatives to the buy-and-bill system have been proposed to include invoice pricing, least costly alternative reimbursement, bundling of drugs into episode-of-care payments, shifting Part B drugs to the Medicare Part D benefit, and revision of the failed Competitive Acquisition Program. This article brings the perspectives of policy makers, health care economists, and providers together to discuss this major challenge in oncology payment reform.
authors.affiliation: From the Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL; Departments of Pediatrics and Public Health Science, The University of Chicago, Chicago, IL; Department of Medical Oncology, Swedish Cancer Institute, Seattle, WA.
authors.forename: Blase
authors.initials: B
authors.lastname: Polite
authors.affiliation: From the Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL; Departments of Pediatrics and Public Health Science, The University of Chicago, Chicago, IL; Department of Medical Oncology, Swedish Cancer Institute, Seattle, WA.
authors.forename: Rena M
authors.initials: RM
authors.lastname: Conti
authors.affiliation: From the Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL; Departments of Pediatrics and Public Health Science, The University of Chicago, Chicago, IL; Department of Medical Oncology, Swedish Cancer Institute, Seattle, WA.
authors.forename: Jeffery C
authors.initials: JC
authors.lastname: Ward
mesh_terms: D000553:Ambulatory Care / Q000191:economics*; D018166:Health Care Reform; D006801:Humans; D008495:Medical Oncology; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics*; D011057:Politics; D013038:Specialization; D014481:United States